This content is from: Portfolio Investing in a Cure for Cancer The recently launched Loncar Cancer Immunotherapy ETF provides investors with a vehicle to bet on promising new immunotherapy treatments for cancer. By Kaitlin Ugolik June 07, 2016
This content is from: Premium Hedge Funds Go Bottom Fishing in Biopharma Over the past few weeks, four different life sciences hedge funds have taken stakes of at least 5 percent in more than a half dozen stocks. By Stephen Taub October 04, 2022
This content is from: Premium Reeling Casdin Receives a Capital Infusion Investors recently poured hundreds of millions of dollars into one of this year’s worst-performing hedge funds. By Stephen Taub July 13, 2022
This content is from: Research The 2014 All-Japan Research Team: Health Care & Pharmaceuticals, No. 2: Hidemaru Yamaguchi April 07, 2014
This content is from: Premium Perceptive Launches Back to Back SPACs The hedge fund filed plans to raise funds for a second blank check company this month. By Stephen Taub July 22, 2020
This content is from: Premium Perceptive Advisors Preps New Blank-Check Company The life sciences specialist’s first special-purpose acquisition company recently announced a deal. By Stephen Taub May 20, 2020
